Close Menu

NEW YORK (360Dx) – Owlstone Medical today announced a strategic collaboration with Actelion Pharmaceuticals to develop a breath-based test for the early diagnosis of pulmonary hypertension (PH) and its subtypes.

San Francisco, California-based Actelion, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, is funding the development program.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.